News
IGC
0.4065
+1.88%
0.0075
'GOP Senators Tell DEA To Reject Marijuana Rescheduling, Arguing It Would Violate International Treaties' - Marijuana Moment
Three Republican senators are urging the DEA to reject a marijuana rescheduling recommendation. The senators say the U.S. Should not move cannabis from Schedule I to Schedule III. They say the move would violate international treaty obligations. Supporters and opponents of rescheduled marijuana have made competing arguments.
Benzinga · 22h ago
IGC Pharma Announces $3M Unregistered Private Placement Of 8,823,529 Shares Of Its Common Stock
IGC Pharma, Inc. Announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited. The funds will support general corporate purposes and the advancement of its investigational medicines including IGC-AD1. IGC will issue 8,823,529 shares of common stock.
Benzinga · 1d ago
'Three In Five Americans Want Congress To Pass Marijuana Banking Reform, American Bankers Associations Poll Finds Amid Renewed Push' - Marijuana Moment
A new poll from the American Bankers Association shows 63 percent of Americans support allowing marijuana businesses access to the banking system. The survey comes amid a renewed push for marijuana banking reform in Congress. The SAFER Banking Act would protect financial institutions that serve state-licensed cannabis businesses.
Benzinga · 3d ago
Weekly Report: what happened at IGC last week (0318-0322)?
Weekly Report · 3d ago
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
GC Pharma Inc (IGC) announced results of an interim analysis of its ongoing Phase 2 trial of IGC-AD1 for agitation in dementia from Alzheimer's disease. The drug shows a statistically significant reduction in agitation compared to placebo in patients with the disease. In 2023, the number of Americans living with Alzheimer’s disease is estimated at 6.7 million.
Benzinga · 03/20 17:21
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
IGC Pharma, Inc. Will participate in a fire chat at the BENZINGA VIRTUAL HEALTHCARE SUMMIT 2024 on March 20, 2024. IGC Pharma is focused on Alzheimer's disease and has a pipeline of five promising drug candidates. The company's mission is to transform the landscape of Alzheimer's treatment.
Barchart · 03/20 06:00
Weekly Report: what happened at IGC last week (0311-0315)?
Weekly Report · 03/18 10:15
India Globalization Capital Welcomes New Board Member
TipRanks · 03/13 13:12
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
IGC Pharma, Inc. Has appointed Terry Lierman as an independent director to its board of directors. IGC Pharma is at the forefront of the fight against Alzheimer's disease. The company has a pipeline of five promising drug candidates for the treatment of the disease.
Barchart · 03/12 14:00
'DEA Officials Reportedly At Odds With Biden Admin Over Marijuana Rescheduling Push' - Marijuana Moment
Wall Street Journal report says DEA officials are at odds with the White House over calls to reschedule marijuana. President Joe Biden has pushed for the drug to be rescheduled from Schedule I to Schedule III. The report says the DEA is unconvinced of scientific findings that cannabis holds medical value.
Benzinga · 03/11 17:21
Weekly Report: what happened at IGC last week (0304-0308)?
Weekly Report · 03/11 10:13
Weekly Report: what happened at IGC last week (0226-0301)?
Weekly Report · 03/04 10:15
12 Health Care Stocks Moving In Wednesday's After-Market Session
IGC Pharma shares moved upwards by 14.6% to $0.4 during Wednesday's after-market session. Establishment Labs Hldgs (NASDAQ:ESTA) shares rose 14.43% during the session. The company's, Q4 earnings came out today. Butterfly Network (NYSE:BFLY) shares decreased by 16.9% in the same session.
Benzinga · 02/28 21:31
IGC Pharma Sees Positive Memory Function Data in Preclinical Study of Alzheimer's Disease Drug
GC Pharma says its Alzheimer's disease drug candidate TGR-63 demonstrated enhanced memory function in preclinical studies. The company is optimistic about the drug's potential. The drug candidate is seen as a candidate for a Phase 1 trial in the disease. The positive data was seen in an Alzheimer's mouse model.
Dow Jones · 02/28 18:37
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
IGC Pharma, Inc. Announces results of preclinical studies investigating its drug candidate TGR-63 as a treatment for Alzheimer's disease. The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval. T GR-63 is a therapeutic candidate designed to disrupt the structure of the amyloid-β peptide.
Barchart · 02/28 12:00
Weekly Report: what happened at IGC last week (0219-0223)?
Weekly Report · 02/26 10:22
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
IGC Pharma, Inc. Is pursuing innovative solutions to fight Alzheimer's disease and related challenges. IGC Pharma's portfolio comprises five assets with a singular mission to transform the landscape of Alzheimer's treatment. The company is at the forefront of Generative AI development. Ascendiant Capital Markets LLC has issued an analyst coverage research report on the Company.
Barchart · 02/23 11:01
'Law Enforcement Leaders Urge Biden To Reclassify Marijuana To Lesser Status' - The Hill
A group of law enforcement leaders urged President Biden to reclassify marijuana to a lesser status in a letter. The group cited the discrepancy between how marijuana is treated at the state and federal levels. 38 states are expected to legalize marijuana by the end of the year. Some Democratic Senators have urged the Biden administration to completely deschedule marijuana.
Benzinga · 02/22 15:31
IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses
IGC Pharma Inc announced its financial results for the third quarter of fiscal year 2024. The company reported a 38% decline in quarterly revenue and a significant net loss of $5.5 million. IGC's shares were trading 1.18% higher at $0.30 at the time of this writing. The pharmaceutical company has a patent for an Alzheimer's therapy.
Benzinga · 02/19 18:17
Weekly Report: what happened at IGC last week (0212-0216)?
Weekly Report · 02/19 10:23
More
Webull provides a variety of real-time IGC stock news. You can receive the latest news about IGC Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IGC
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.